Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Syndax Pharmaceuticals, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
About This Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX).
On October 12, 2026, Syndax Pharmaceuticals announced that its Phase 2 MAXPIRe clinical trial evaluating axatilimab failed to meet its primary endpoint. Following this news, Syndax’s stock price declined more than 15.7% on October 13, 2026.
What We Are Investigating
- Whether Syndax Pharmaceuticals, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Syndax Pharmaceuticals, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Investors Should Do
SNDX — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”